AKB 9778

Drug Profile

AKB 9778

Alternative Names: AKB-9089; AKB-9778; AKB-9875; HPTP-beta mAb - Aerpio

Latest Information Update: 21 Mar 2017

Price : $50

At a glance

  • Originator Procter & Gamble
  • Developer Aerpio Pharmaceuticals; Duke University; Harvard Medical School; Johns Hopkins University School of Medicine; Massachusetts General Hospital; Massachusetts Institute of Technology; Max Planck Institute for Molecular Biomedicine; New York University
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action Angiopoietin modulators; Receptor-like protein tyrosine phosphatase inhibitors; TIE receptor agonists; TIE-2 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Diabetic macular oedema; Retinal vein occlusion
  • Preclinical Age-related macular degeneration; Breast cancer

Most Recent Events

  • 16 Mar 2017 Aerpio Pharmaceuticals plans a phase IIb trial for Diabetic retinopathy without diabetic macular oedema
  • 15 Mar 2017 Zeta Acquisition Corp II in a reverse merger transaction acquires Aerpio Therapeutics and changes its name to Aerpio Pharmaceuticals
  • 11 Feb 2016 Positive efficacy data from a phase IIa trial in Diabetic macular oedema released by Aerpio Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top